NCT00101946 - Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions

Crohn's Disease

Interventions

DRUG

683699

Trial Locations (19)

11021

GSK Investigational Site, Great Neck

27612

GSK Investigational Site, Raleigh

28211

GSK Investigational Site, Charlotte

29681

GSK Investigational Site, Simpsonville

33173

GSK Investigational Site, Miami

38120

GSK Investigational Site, Memphis

45219

GSK Investigational Site, Cincinnati

66614

GSK Investigational Site, Topeka

77030

GSK Investigational Site, Houston

92840

GSK Investigational Site, Garden Grove

95661

GSK Investigational Site, Roseville

97504

GSK Investigational Site, Medford

02673

GSK Investigational Site, West Yarmouth

T2N 4N1

GSK Investigational Site, Calgary

M3N 2V7

GSK Investigational Site, Toronto

N8X 5A6

GSK Investigational Site, Windsor

G6V 3Z1

GSK Investigational Site, Lévis

G1S 4L8

GSK Investigational Site, Québec

S7K 1J5

GSK Investigational Site, Saskatoon